These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
228 related articles for article (PubMed ID: 38713534)
1. Differential effects of FcRn antagonists on the subcellular trafficking of FcRn and albumin. Ma G; Crowley AR; Heyndrickx L; Rogiers I; Parthoens E; Van Santbergen J; Ober RJ; Bobkov V; de Haard H; Ulrichts P; Hofman E; Louagie E; Balbino B; Ward ES JCI Insight; 2024 May; 9(10):. PubMed ID: 38713534 [TBL] [Abstract][Full Text] [Related]
2. Differential trafficking of albumin and IgG facilitated by the neonatal Fc receptor in podocytes in vitro and in vivo. Dylewski J; Dobrinskikh E; Lewis L; Tonsawan P; Miyazaki M; Jat PS; Blaine J PLoS One; 2019; 14(2):e0209732. PubMed ID: 30811433 [TBL] [Abstract][Full Text] [Related]
3. Albumin binding to FcRn: distinct from the FcRn-IgG interaction. Chaudhury C; Brooks CL; Carter DC; Robinson JM; Anderson CL Biochemistry; 2006 Apr; 45(15):4983-90. PubMed ID: 16605266 [TBL] [Abstract][Full Text] [Related]
4. Generation of a double transgenic humanized neonatal Fc receptor (FcRn)/albumin mouse to study the pharmacokinetics of albumin-linked drugs. Viuff D; Antunes F; Evans L; Cameron J; Dyrnesli H; Thue Ravn B; Stougaard M; Thiam K; Andersen B; Kjærulff S; Howard KA J Control Release; 2016 Feb; 223():22-30. PubMed ID: 26699424 [TBL] [Abstract][Full Text] [Related]
5. FcRn binding properties of an abnormal truncated analbuminemic albumin variant. Andersen JT; Daba MB; Sandlie I Clin Biochem; 2010 Mar; 43(4-5):367-72. PubMed ID: 20006594 [TBL] [Abstract][Full Text] [Related]
6. Extended plasma half-life of albumin-binding domain fused human IgA upon pH-dependent albumin engagement of human FcRn Mester S; Evers M; Meyer S; Nilsen J; Greiff V; Sandlie I; Leusen J; Andersen JT MAbs; 2021; 13(1):1893888. PubMed ID: 33691596 [TBL] [Abstract][Full Text] [Related]
7. The Neonatal Fc Receptor (FcRn): A Misnomer? Pyzik M; Sand KMK; Hubbard JJ; Andersen JT; Sandlie I; Blumberg RS Front Immunol; 2019; 10():1540. PubMed ID: 31354709 [TBL] [Abstract][Full Text] [Related]
8. FcRn, but not FcγRs, drives maternal-fetal transplacental transport of human IgG antibodies. Borghi S; Bournazos S; Thulin NK; Li C; Gajewski A; Sherwood RW; Zhang S; Harris E; Jagannathan P; Wang LX; Ravetch JV; Wang TT Proc Natl Acad Sci U S A; 2020 Jun; 117(23):12943-12951. PubMed ID: 32461366 [TBL] [Abstract][Full Text] [Related]
9. Monoclonal antibodies directed against human FcRn and their applications. Christianson GJ; Sun VZ; Akilesh S; Pesavento E; Proetzel G; Roopenian DC MAbs; 2012; 4(2):208-16. PubMed ID: 22453095 [TBL] [Abstract][Full Text] [Related]
10. Direct demonstration of a neonatal Fc receptor (FcRn)-driven endosomal sorting pathway for cellular recycling of albumin. Schmidt EGW; Hvam ML; Antunes F; Cameron J; Viuff D; Andersen B; Kristensen NN; Howard KA J Biol Chem; 2017 Aug; 292(32):13312-13322. PubMed ID: 28637874 [TBL] [Abstract][Full Text] [Related]
11. Neonatal Fc receptor blockade by Fc engineering ameliorates arthritis in a murine model. Patel DA; Puig-Canto A; Challa DK; Perez Montoyo H; Ober RJ; Ward ES J Immunol; 2011 Jul; 187(2):1015-22. PubMed ID: 21690327 [TBL] [Abstract][Full Text] [Related]
12. Single-chain variable fragment albumin fusions bind the neonatal Fc receptor (FcRn) in a species-dependent manner: implications for in vivo half-life evaluation of albumin fusion therapeutics. Andersen JT; Cameron J; Plumridge A; Evans L; Sleep D; Sandlie I J Biol Chem; 2013 Aug; 288(33):24277-85. PubMed ID: 23818524 [TBL] [Abstract][Full Text] [Related]
13. Extending half-life by indirect targeting of the neonatal Fc receptor (FcRn) using a minimal albumin binding domain. Andersen JT; Pehrson R; Tolmachev V; Daba MB; Abrahmsén L; Ekblad C J Biol Chem; 2011 Feb; 286(7):5234-41. PubMed ID: 21138843 [TBL] [Abstract][Full Text] [Related]
14. The neonatal Fc receptor: Key to homeostasic control of IgG and IgG-related biopharmaceuticals. Baldwin WM; Valujskikh A; Fairchild RL Am J Transplant; 2019 Jul; 19(7):1881-1887. PubMed ID: 30903736 [TBL] [Abstract][Full Text] [Related]
16. Are endosomal trafficking parameters better targets for improving mAb pharmacokinetics than FcRn binding affinity? Gurbaxani B; Dostalek M; Gardner I Mol Immunol; 2013 Dec; 56(4):660-74. PubMed ID: 23917469 [TBL] [Abstract][Full Text] [Related]
17. Combined glyco- and protein-Fc engineering simultaneously enhance cytotoxicity and half-life of a therapeutic antibody. Monnet C; Jorieux S; Souyris N; Zaki O; Jacquet A; Fournier N; Crozet F; de Romeuf C; Bouayadi K; Urbain R; Behrens CK; Mondon P; Fontayne A MAbs; 2014; 6(2):422-36. PubMed ID: 24492301 [TBL] [Abstract][Full Text] [Related]
18. Interaction with both domain I and III of albumin is required for optimal pH-dependent binding to the neonatal Fc receptor (FcRn). Sand KM; Bern M; Nilsen J; Dalhus B; Gunnarsen KS; Cameron J; Grevys A; Bunting K; Sandlie I; Andersen JT J Biol Chem; 2014 Dec; 289(50):34583-94. PubMed ID: 25344603 [TBL] [Abstract][Full Text] [Related]
19. The immunologic functions of the neonatal Fc receptor for IgG. Rath T; Kuo TT; Baker K; Qiao SW; Kobayashi K; Yoshida M; Roopenian D; Fiebiger E; Lencer WI; Blumberg RS J Clin Immunol; 2013 Jan; 33 Suppl 1(Suppl 1):S9-17. PubMed ID: 22948741 [TBL] [Abstract][Full Text] [Related]
20. N-Glycan Moieties in Neonatal Fc Receptor Determine Steady-state Membrane Distribution and Directional Transport of IgG. Kuo TT; de Muinck EJ; Claypool SM; Yoshida M; Nagaishi T; Aveson VG; Lencer WI; Blumberg RS J Biol Chem; 2009 Mar; 284(13):8292-300. PubMed ID: 19164298 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]